The activated drug targets PSEN, NCSTN and IKKs in Table 1A and the activated drug targets TRAF2 and CK1 in Table 1B are considered as the most effective drug target for preventing MDS and AML leukemogenesis, respectively. This evidence concerns the gene TRAF2 and myelodysplastic syndrome.